NDAORALCAPSULEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Clinical Trials (5)
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Started Mar 2026
52 enrolled
High Grade GliomaCNS Tumor
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Started Nov 2025
30 enrolled
Haematological MalignancyMalignancyMalignant Neoplasm+8 more
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
Started Oct 2022
13 enrolled
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Started Sep 2021
220 enrolled
Carcinoma, Non-Small-Cell Lung
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Started Jan 2021
6 enrolled
Uveal Melanoma